Dendreon (NASDAQ: [[ticker:DNDN]]), the Seattle-based developer of immune-boosting therapies for cancer, said today that the New England Journal of Medicine has published results from the study of 512 men with prostate cancer that led to the FDA approval of sipuleucel-T (Provenge). The study showed Provenge could extend lifespan with minimal side effects back in April 2009, and details were presented publicly at the American Urological Association meeting that month. The drug was cleared for sale by the FDA almost exactly a year later. For a couple different takes on what others have to say about today’s NEJM paper, read Matt Herper’s story at Forbes or Adam Feuerstein at TheStreet.com.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
